INMED PHARMACEUTICALS INC. Increase (Decrease) in Contract with Customer, Liability
INMED PHARMACEUTICALS INC. (INM) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2025-06-30, per its S-4 filed 2026-07-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-07-02
- INMED PHARMACEUTICALS INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was $0.00.
- INMED PHARMACEUTICALS INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was -$28.66K.
- INMED PHARMACEUTICALS INC. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was $28.66K.
- INMED PHARMACEUTICALS INC. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was -$16.17K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 S-4 · filed 2026-07-02 | |||
| 2024-06-30 | $0.00 derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | -$28.66K derived: sum of 2 quarters · filed 2026-07-02 | $0.00 derived: sum of 3 quarters · filed 2026-07-02 | -$16.17K S-4 · filed 2026-07-02 |
| 2024-03-31 | -$28.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2025-05-12 | -$16.17K 10-Q · filed 2025-05-12 | |
| 2023-12-31 | $28.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | $12.48K 10-Q · filed 2025-02-12 | ||
| 2023-09-30 | -$16.17K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |